Immunovaccine Inc. ("Immunovaccine" or the "Company") (TSX VENTURE:IMV), a
clinical stage vaccine company, today announced the addition of Scott Halperin,
M.D., to the Company's scientific advisory board (SAB). Dr. Halperin strengthens
the SAB's broad expertise in infectious disease vaccine research and
development, particularly in the area of clinical trial design and execution. He
will offer critical guidance and insight to Immunovaccine as the company
continues to expand and advance its growing pipeline of infectious disease
vaccines in such indications as malaria, respiratory syncytial virus (RSV) and
anthrax. 


"Dr. Halperin's experience and reputation will add significant value to the SAB
as we begin our clinical development efforts for several infectious disease
vaccines," said John Trizzino, chief executive officer of Immunovaccine. "I am
pleased he will be joining to help us advance our strategy and programs in this
area." 


Immunovaccine has been collaborating with Dr. Halperin and his team at the
Canadian Center for Vaccinology for several years. Evaluating the Company's
technology in his well-established pertussis models has demonstrated the
potential of DepoVax to create a single dose vaccine in this preclinical
challenge model. 


"Through my years of collaborating with the Immunovaccine team, I have been
impressed with the potential of the company's DepoVax platform to enhance the
performance of vaccine candidates," stated Dr. Halperin. "I am excited to join
the other scientists on the company's SAB and offer the insights that I have in
the area of vaccine research and development."


About Scott Halperin, M.D.

Dr. Halperin's numerous professional positions include: professor of pediatrics
and microbiology and immunology at Dalhousie University; head of infectious
diseases at the IWK Health Centre in Halifax, Nova Scotia; and, director of the
Canadian Center for Vaccinology, a joint collaboration of the IWK Health Centre,
Capital Health, and Dalhousie University. 


As one of the world's leading authorities on the development of vaccines, his
research focuses on the diagnosis, treatment, and prevention of pertussis
(whooping cough) and other vaccine-preventable diseases such as influenza. His
research in the area of pertussis has sparked improved diagnosis, treatment and
prevention of this life-threatening disease and his team is credited with
developing one of the pertussis vaccines that is now used around the world. Dr.
Halperin is also principal investigator of the $13.5 million Public Health
Agency of Canada/Canadian Institutes of Health Research Influenza Research
Network (PCIRN). This group connects most of the major medical research
institutions and universities across Canada, in an effort to ensure the safety
and effectiveness of influenza vaccines and vaccination programs and to train
the next generation of clinical vaccine researchers. 


He earned his undergraduate degree in biology from Stanford University and his
medical degree from Cornell University. He conducted his postgraduate residency
training in pediatrics at the University of Virginia and his fellowship in
pediatric infectious diseases at the University of Virginia and the University
of Minnesota.


About Immunovaccine

Immunovaccine Inc. applies its novel adjuvanting platform to the development of
vaccines for cancer therapy, infectious diseases and animal health. The
Company's DepoVax(TM) platform is a patented formulation that provides
controlled and prolonged exposure of antigens plus adjuvant to the immune
system. Immunovaccine has advanced two DepoVax-based cancer vaccines into Phase
I human clinical trials. The Company is also advancing a broad infectious
disease pipeline including vaccines in such indications as malaria, respiratory
syncytial virus (RSV) and anthrax. In addition to the Company's human health
vaccine strategy, it continues to capture value from animal health vaccine
applications. Immunovaccine has key partnerships in the animal health sector
including an agreement with Pfizer Animal Health. Connect at www.imvaccine.com.


This press release contains forward-looking information under applicable
securities law. All information that addresses activities or developments that
we expect to occur in the future is forward-looking information. Forward-looking
statements are based on the estimates and opinions of management on the date the
statements are made. However, they should not be regarded as a representation
that any of the plans will be achieved. Actual results may differ materially
from those set forth in this press release due to risks affecting the company,
including access to capital, the successful completion of clinical trials and
receipt of all regulatory approvals. Immunovaccine Inc. assumes no
responsibility to update forward-looking statements in this press release.